Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-PSMA-11 PET/MRI for HCC
NCT03982407Phase 1Completed
- Start
- Jun 2019
- Primary completion
- May 2021
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium ga-68 gozetotide in hepatocellular carcinoma (HCC). Primary endpoints: Feasibility of 68Ga-PSMA-PET/MRI at 18 months, Sensitivity of SUVmax on PSMA PET at 18 months and 1 more. Started Jun 2019; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03982407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982407.